David Hockenbery, MD


David Hockenbery, MD

Clinical Research Division, Fred Hutch

Human Biology Division, Fred Hutch

Public Health Sciences Division, Fred Hutch

Fax: 206.667.6519
Mail Stop: D2-190

Dr. David Hockenbery is a clinical researcher who studies the biology of programmed cell death, or apoptosis, the process by which cells commit suicide when diseased or no longer needed. His research focuses on cell-death processes that are defective in many cancer cells, allowing them to grow unchecked. His team explores how cell metabolism — the step-by-step processes cells use to break down nutrients — is used to control programmed cell death in both normal and cancer cells. Cancer cells use a variety of metabolic processes to suppress apoptosis, and Dr. Hockenberry’s team is exploring how these same processes might affect the performance of immune cells in the presence of infectious agents or cancer.


Washington University School of Medicine, MD, 1982

Research Interests

The Hockenbery lab studies programmed cell death (apoptosis) pathways that are defective in many cancer cells; and the role of cancer-cell metabolism in apoptosis, oncogene functions, and environmental/dietary risk factors, including excess supply of nutrients. After identifying cancer-selective targets, they carry out small-molecule screens for inhibitors to identify lead compounds as anticancer agents.

Find a Clinical Trial Led by Dr. Hockenbery

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210